California Based Startup ‘Grail’ Develops Pan-Cancer Screening Test Designed to Detect Cancers at an Early Stage
| < 1 minute read
Headquartered in: Menlo Park, California, United States
Founders: Alex Aravanis, Jeff Huber, Mostafa Ronaghi
Founded date: 2016
Hub tags: Exited Unicorn
Grail pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.
Grail plans to launch Galleri, a lab-developed test to detect cancers early in the blood, commercially next year. The company says the test has greater than 99% specificity and 93% tissue-of-origin accuracy to detect at least 50 cancers, with 43% positive predictive value and 44% sensitivity for all cancer types.
According to Grail, late diagnosis of cancers can lead to a 79% mortality rate at five years, compared with just 11% when they are diagnosed early.
Several companies have been developing tests for early cancer detection. These include Thrive Earlier Detection, which raised a $257 million Series B funding round that it will use to fund its registration-directed clinical study. The challenge in earlier detection is overcoming false positives, with even rates as low as 1% making a potentially big difference because, in larger populations, it can mean many patients still having to undergo tissue biopsy.
About the author
Get Updates To Your Inbox
Corefactors has seen struggles in maintaining leads for a business, tracking the team’s progress, and accessing reports in a conventional excel sheet. While all of this led to the inefficiency of the business functioning, it also added the difficulty of juggling between various platforms. Intending to shove away the roadblocks in the way of business sales, marketing, and communication, Corefactors understood the gap. That’s how Teleduce emerged into the business as an “ Integrated CRM to empower marketing, sales, and support teams with inbuilt cloud telephony.”